Quickly detect multiple antigens in a single tissue section to gain clear understanding of the microenvironment without compromising samples. To serve your multiplex research needs, Bethyl introduces IHC PathPlex™ panels to profile the complex tumor microenvironment. Each antibody has been validated for IHC and utilized in a multiplex format by our own scientists via proprietary processes to ensure the highest quality.
Bethyl has applied B-cell sorting and recombinant DNA technology to our unparalleled on-site manufacturing process to deliver high quality recombinant rabbit monoclonal antibodies (RmAbs). Designed with a 100% guarantee to work in validated applications to ensure that you spend less time re-doing experiments and more time researching.
Immune checkpoint blockade has emerged over the past decade as a useful therapeutic tool against many types of tumors. The most commonly known checkpoint that can be targeted therapeutically is the PD-1/PD-L1 pathway. Bethyl's new PD-L1 recombinant rabbit monoclonal antibody was compared against the leading competitor's antibody and proved to be 8 times more sensitive.
Trial sizes are ideal for comparisons between suppliers or various application testings and cost effective at $99 US. Over 6,000 trial-sized antibodies are available to more than 3,300 protein targets, and new releases are continuing to be added every month.
Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.